- Current report filing (8-K)
2011年1月11日 - 7:14AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): January 10, 2011
Adeona
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in charter)
Nevada
(State or
other jurisdiction of incorporation)
01-12584
(Commission
File Number)
|
13-3808303
(IRS
Employer Identification No.)
|
3930
Varsity Drive
Ann Arbor, MI
48108
|
|
(Address
of principal executive offices and zip
code)
|
|
|
(Registrant’s
telephone number including area
code)
|
|
|
(Former
Name and Former
Address)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01
Regulation FD Disclosure.
Dr. James
S. Kuo, Chairman and Chief Executive Officer of the registrant, is making
presentations to analysts, potential investors and shareholders. A
copy of the visual presentation in substantially the form that is being used by
Dr. Kuo is being furnished as Exhibit 99.1 to this Report and is incorporated
herein by reference.
This
information and the Exhibit attached hereto are being “furnished” pursuant to
Item 7.01 and in accordance with General Instruction B.2 to Form 8-K shall
not be deemed “filed” with the Securities and Exchange Commission for purposes
of Section 18 of the Securities Exchange Act of 1934 or otherwise subject
to the liabilities under that section, nor shall such information be deemed to
be incorporated by reference into any filings under the Securities Act of
1933.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Slides
used in presentation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: January
10, 2011
|
Adeona
Pharmaceuticals, Inc.
|
|
(Registrant)
|
|
|
|
By:
/s/ James S.
Kuo
|
|
Name:
James S. Kuo
|
|
Title:
Chief Executive Officer
|
Adeona Pharmaceuticals Common Stock (AMEX:AEN)
過去 株価チャート
から 6 2024 まで 7 2024
Adeona Pharmaceuticals Common Stock (AMEX:AEN)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Adeona Pharmaceuticals Common Stock (アメリカ証券取引所): 0 recent articles
その他のニュース記事